| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6119833 | Journal of Clinical Virology | 2015 | 8 Pages |
Abstract
Dolutegravir may potentially be effective in the majority of HIV-1 patients failing raltegravir, but concern over the uncertainty in predicted residual activity could withhold clinicians from prescribing dolutegravir during its clinical assessment.
Related Topics
Life Sciences
Immunology and Microbiology
Applied Microbiology and Biotechnology
Authors
Kristof Theys, Ana Abecasis, Pieter Libin, Perpétua Gomes, Joaquim Cabanas, Ricardo J. Camacho, Kristel Van Laethem,